177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Hospital Universitario 12 De Octubre · Royal Marsden Hospital · +21 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
245
total citations
- FWCI
- 91.04
- Percentile
- 100%
- References
- 50
Citations per year
Authors
23Topics & keywords
Topics
Keywords
- Medicine
- Taxane
- Prostate cancer
- Oncology
- Androgen receptor
- Internal medicine
- Androgen deprivation therapy
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- BBayer
- GGlaxoSmithKline
- NNovartis
- SSanofi
- LMLantheus Medical Imaging
- NPNovartis Pharmaceuticals Corporation
- EEndocyte
- BSBoston Scientific Corporation
- BBeiGene
- UPUroGen Pharma
- MMacroGenics
- IInvitae
- DDaiichi-Sankyo
- APAstellas Pharma
- IIpsen
- NINational Institutes of Health
- GGenentech
- SGSanofi Genzyme
- MRMedical Research CouncilAward: MR/W018217/1
- NCNational Cancer InstituteAward: P30 CA008748